Side-by-side · Research reference
KPVvsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BPhase 2Reviewed8/46 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
KPV
TB-500
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
No melanocortin receptor binding
Endogenous protein at baseline; supplementation amplifies
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
TB-500
Standard dose
200–500 mcg / day SQ or oralDalle-Pang 2024
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
Daily or 2–3× per week
2× per week (loading); then 1× per week (maintenance)
Lower / starter dose
100 mcg / day
1 mg per injection
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Duration
4–8 weeks per cycle
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
Bacteriostatic water (SQ form)
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
No specific time; often taken with / before meals (oral)
Evening or pre-rest preferred (anecdotal)
Half-life
Hours (estimated; rapid tissue uptake)
~2 hours (estimated; tissue uptake longer)
04Side Effects & Safety
Parameter
KPV
TB-500
Injection site reaction
Mild irritation
Mild erythema, transient pain
GI symptoms
Rare nausea (oral form)
Rare nausea (anecdotal)
Long-term safety
Limited human data
Unknown beyond Phase 2
Pregnancy / OB
Avoid — insufficient data
Avoid
Cancer risk
—
Theoretical via angiogenesis pathway
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
KPV
TB-500
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Timing
Morning preferred; oral form taken with / before meals.
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
29–31G insulin syringe (SQ form).
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair